<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Mdxhealth Sa Adr — News on 6ix</title>
<link>https://6ix.com/company/mdxhealth-sa-adr</link>
<description>Latest news and press releases for Mdxhealth Sa Adr on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 16 Mar 2026 20:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/mdxhealth-sa-adr" rel="self" type="application/rss+xml" />
<item>
<title>Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-highlights-data-from-oxfords-prompt-study-demonstrating-the-genomic-prostate-score-gps-test-predicts-adverse-outcomes-across-multiple-treatment-settings-at-eau-2026</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-highlights-data-from-oxfords-prompt-study-demonstrating-the-genomic-prostate-score-gps-test-predicts-adverse-outcomes-across-multiple-treatment-settings-at-eau-2026</guid>
<pubDate>Mon, 16 Mar 2026 20:00:00 GMT</pubDate>
<description>Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 IRVINE, California – March 16, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that new data demonstrating the prognostic value of the Genomic Prostate Score (GPS mdx) test across multiple treatment strategies were present</description>
</item>
<item>
<title>Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-announces-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-announces-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results Fourth quarter revenue growth of 19% to $29.5 million2025 revenue growth of 20% to</description>
</item>
<item>
<title>Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-present-fourth-quarter-full-220000555</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-present-fourth-quarter-full-220000555</guid>
<pubDate>Thu, 12 Feb 2026 22:00:00 GMT</pubDate>
<description>Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – February 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026. Title:</description>
</item>
<item>
<title>MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-reports-preliminary-fourth-quarter-130000378</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-reports-preliminary-fourth-quarter-130000378</guid>
<pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
<description>MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences IRVINE, CA – January 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2025 revenues and issued 2026 revenue guidance. The Company expects to report fourth quarter and full year 2025 revenues of approximately $30.5 mi</description>
</item>
<item>
<title>Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-university-oxford-validate-gps-130000819</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-university-oxford-validate-gps-130000819</guid>
<pubDate>Tue, 06 Jan 2026 13:00:00 GMT</pubDate>
<description>Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer IRVINE, CA – January XX, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leading precision diagnostics company, today announced the next major phase of its collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial (Prostate Testing fo</description>
</item>
<item>
<title>Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-reports-results-third-quarter-210100833</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-reports-results-third-quarter-210100833</guid>
<pubDate>Wed, 12 Nov 2025 21:01:00 GMT</pubDate>
<description>Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025 Q3 revenues increased by 18% to $27.4 millionAdjusted EBITDA profitability of $1.0 million for Q3Acquisition of ExoDx business from Bio-Techne CorporationConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA – November 12, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for th</description>
</item>
<item>
<title>Mdxhealth to Release Third Quarter 2025 Financial Results on November 12</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-release-third-quarter-2025-210100614</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-release-third-quarter-2025-210100614</guid>
<pubDate>Mon, 03 Nov 2025 21:01:00 GMT</pubDate>
<description>Mdxhealth to Release Third Quarter 2025 Financial Resultson November 12 Company to Host Conference Call with Live Q&A, November 12, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – November 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the third quarter ended September 30, 2025, after market close on Wednesday, November 12, 2025. Title:Mdxhealth Presents Third Quarter 2025 Financial Res</description>
</item>
<item>
<title>Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-announces-closing-exosome-diagnostics-212900554</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-announces-closing-exosome-diagnostics-212900554</guid>
<pubDate>Mon, 15 Sep 2025 21:29:00 GMT</pubDate>
<description>Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne IRVINE, CA, and HERSTAL, BELGIUM – September 15, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the closing of the ExoDx business acquisition from Bio-Techne Corporation, which includes the ExoDx Prostate test. Acquisition of ExoDx Business On August 5, 2025, mdxhealth signed a definitive agreement to acquire Exosome Diagnosti</description>
</item>
<item>
<title>Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-reports-preliminary-second-quarter-200100067</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-reports-preliminary-second-quarter-200100067</guid>
<pubDate>Tue, 05 Aug 2025 20:01:00 GMT</pubDate>
<description>Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Year-over-year Q2 revenues increased by 20% to $26.6 millionAdjusted EBITDA profitability of $1.4 million for Q2 Agreement to acquire ExoDx Business from Bio-Techne for $15 million in cash and stock over 5 years; acquisition expected to accelerate revenue growth and be accretive to adjusted EBITDA Conference call with Q&A today at</description>
</item>
<item>
<title>Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-appoints-michael-holder-board-170000113</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-appoints-michael-holder-board-170000113</guid>
<pubDate>Thu, 03 Jul 2025 17:00:00 GMT</pubDate>
<description>IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles</description>
</item>
<item>
<title>MDxHealth Reports Q1-2025 Results</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-reports-q1-2025-results-200000146</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-reports-q1-2025-results-200000146</guid>
<pubDate>Wed, 14 May 2025 20:00:00 GMT</pubDate>
<description>Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: “mdxhealth deliver</description>
</item>
<item>
<title>Mdxhealth to Release First Quarter 2025 Financial Results on May 14</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-release-first-quarter-2025-200000331</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-release-first-quarter-2025-200000331</guid>
<pubDate>Wed, 30 Apr 2025 20:00:00 GMT</pubDate>
<description>Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief</description>
</item>
<item>
<title>Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-announces-fourth-quarter-full-210000185</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-announces-fourth-quarter-full-210000185</guid>
<pubDate>Wed, 26 Feb 2025 21:00:00 GMT</pubDate>
<description>Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement in adjusted EBITDA in fourth quarterConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Michael K. McGarrity, CEO o</description>
</item>
<item>
<title>MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-reports-preliminary-fourth-quarter-and-full-year-2024-revenues-and-issues-2025-revenue-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-reports-preliminary-fourth-quarter-and-full-year-2024-revenues-and-issues-2025-revenue-guidance</guid>
<pubDate>Mon, 13 Jan 2025 05:00:00 GMT</pubDate>
<description>MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance IRVINE, CA – January 13, 2025 (GlobeNewswire) –</description>
</item>
<item>
<title>MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-reports-results-for-the-third-quarter-and-nine-month-period-ended-september-30-2024</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-reports-results-for-the-third-quarter-and-nine-month-period-ended-september-30-2024</guid>
<pubDate>Wed, 06 Nov 2024 05:00:00 GMT</pubDate>
<description>Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth</description>
</item>
<item>
<title>MDxHealth to Present Third Quarter 2024 Financial Results and Corporate Update on November 6</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-to-present-third-quarter-2024-financial-results-and-corporate-update-on-november-6</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-to-present-third-quarter-2024-financial-results-and-corporate-update-on-november-6</guid>
<pubDate>Mon, 14 Oct 2024 04:00:00 GMT</pubDate>
<description>MDxHealth to Present Third Quarter 2024 Financial Resultsand Corporate Update on November 6 Company to Host Conference Call with Live Q&A, November 6, 2024,</description>
</item>
<item>
<title>MDxHealth Announces Pricing of Offering of Ordinary Shares</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-announces-pricing-of-offering-of-ordinary-shares</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-announces-pricing-of-offering-of-ordinary-shares</guid>
<pubDate>Wed, 25 Sep 2024 04:00:00 GMT</pubDate>
<description>MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH)</description>
</item>
<item>
<title>MDxHealth Announces Launch of Offering of Ordinary Shares</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-announces-launch-of-offering-of-ordinary-shares</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-announces-launch-of-offering-of-ordinary-shares</guid>
<pubDate>Wed, 25 Sep 2024 04:00:00 GMT</pubDate>
<description>MDxHealth Announces Launch of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM –September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH)</description>
</item>
<item>
<title>MDxHealth Reports Q2 and Half Year 2024 Results</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-reports-q2-and-half-year-2024-results</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-reports-q2-and-half-year-2024-results</guid>
<pubDate>Wed, 21 Aug 2024 04:00:00 GMT</pubDate>
<description>MDxHealth Reports Q2 and Half Year 2024 Results Year-over-year Q2 revenues increase by 32% to $22.2 millionYear-over-year H1 revenues increase by 34% to 42.0</description>
</item>
<item>
<title>MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21</title>
<link>https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-to-present-second-quarter-and-first-half-2024-financial-results-and-corporate-update-on-august-21</link>
<guid isPermaLink="true">https://6ix.com/company/mdxhealth-sa-adr/news/mdxhealth-to-present-second-quarter-and-first-half-2024-financial-results-and-corporate-update-on-august-21</guid>
<pubDate>Mon, 12 Aug 2024 04:00:00 GMT</pubDate>
<description>MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 Company to Host Conference Call with Live Q&A,</description>
</item>
</channel>
</rss>